Drug or treatment

Rocbrutinib clinical trials

• 7Clinical trials
• 2Countries

Newest trials

All recruiting trials (7)

• Rocbrutinib in PRL-Positive Relapsing-Remitting MS

  This study tests whether Rocbrutinib can help people with relapsing-remitting MS who have paramagnetic rim lesions, compared to dimethyl fumarate.

  Recruiting Phase 2 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality · NCT07776743

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Rocbrutinib plus R-GemOx for relapsed/refractory DLBCL

  This early-stage study tests whether combining Rocbrutinib with R-GemOx is safe and shows promise in people with relapsed or refractory non-GCB DLBCL.

  Recruiting at 2 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Guangzhou, Guangdong and 1 other locations · NCT07570017

• Rocbrutinib versus other BTK inhibitors for relapsed or refractory mantle cell lymphoma

  This trial tests whether rocbrutinib works better than other BTK inhibitors for people with mantle cell lymphoma that returned or didn't respond after at least one prior treatment and who have not previously received a BTK inhibitor (except for intolerance).

  Recruiting Phase 3 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality and 1 other locations · NCT07377578

• Effects of itraconazole or rifampin on rocbrutinib levels in healthy adults.

  This test will see if the antifungal itraconazole or the antibiotic rifampin change how rocbrutinib is absorbed, distributed, and cleared in healthy adults.

  Recruiting Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Beijing, Beijing Municipality · NCT07374224

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• Rocbrutinib for adults with relapsed or refractory non‑GCB diffuse large B‑cell lymphoma

  This test tries rocbritinib alone versus the doctor's choice of bendamustine‑rituximab or lenalidomide‑rituximab in adults whose non‑GCB diffuse large B‑cell lymphoma has relapsed or not responded after at least two prior treatments.

  Recruiting at 2 sites Phase 2 Guangzhou Lupeng Pharmaceutical Company LTD. · Hefei, Anhui and 40 other locations · NCT07189065

Quick answers

How many clinical trials of Rocbrutinib are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (6 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2, Phase 3: 2, Phase 1: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →